Stereospecific synthesis of 5-substituted 2-bisarylthiocyclopentane carboxylic acids as specific matrix metalloproteinase inhibitors

Journal of Medicinal Chemistry

Volumn 46, Issue 18, 2003, Pages 3840-3852

  Le Diguarher, Thierry ^a   Chollet, Anne Marie ^a   Bertrand, Marc ^b   Hennig, Philippe ^a   Raimbaud, Eric ^a   Sabatini, Massimo ^a   Guilbaud, Nicolas ^a   Pierré, Alain ^a   Tucker, Gordon C ^a   Casara, Patrick ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 (4' CHLOROBIPHENYL)ETHYLSULFONYL] 5 (PHTHALIMIDOMETHYL)CYCLOPENTANECARBOXYLIC ACID; 2 [2 (4' CHLOROBIPHENYL)ETHYLTHIO] 5 (PHTHALIMIDOMETHYL)CYCLOPENTANECARBOXYLIC ACID; 2 [2 (4' CHLOROBIPHENYL)ETHYLTHIO] 5 [2 (4 OXO 4H BENZO[D][1,2,3]TRIAZIN 3 YLMETHYL)]CYCLOPENTANECARBOXYLIC ACID; 2 [2 (4' CHLOROBIPHENYLTHIO)] 5 [2 (4 OXO 4H BENZO[D][1,2,3]TRIAZIN 3 YL METHYL)]CYCLOPENTANECARBOXYLIC ACID; 2 [2 (4' FLUOROBIPHENYL)ETHYLTHIO] 5 (PHTHALIMIDOMETHYL)CYCLOPENTANECARBOXYLIC ACID; CARBOXYLIC ACID DERIVATIVE; CGS 27023A; CIPEMASTAT; COLLAGENASE 3; CYCLOPENTANE DERIVATIVE; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PRINOMASTAT; STROMELYSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG CONFORMATION; DRUG POTENCY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LUNG METASTASIS; MELANOMA; MOUSE; NONHUMAN; RAT; STEREOCHEMISTRY; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CYCLOPENTANES; HUMANS; MATRIX METALLOPROTEINASES; MELANOMA, EXPERIMENTAL; MICE; MICROSOMES, LIVER; MODELS, MOLECULAR; MOLECULAR CONFORMATION; NEOPLASM METASTASIS; PERMEABILITY; PHTHALIMIDES; PROTEASE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES;

EID: 0042929694     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0307638     Document Type: Article

References (43)

1. (a) Nagase, H.; Woessner, J. F., Jr. Matrix Mettaloproteinases. J. Biol. Chem. 1999, 274, 21491-21494,
2. (b) Birkedal-Hansen, H.; Moore, W. G. I.; Bodden, M. K.; Windsor, L. J.; Birkedal-Hansen, B.; DeCarlo, A.; Engler, J. A. Matrix Mettaloproteinases: A Review. Crit. Rev. Oral Biol. Med. 1993, 4, 197-250.
3. (a) Billinghurst, R. C.; Dahlberg, L.; Ionescu, M.; Reiner, A.; Bourne, R.; Rorabeck, C.; Mitchell, P.; Hambor, J.; Diekmann, O.; Tschesche, H.; Chen, J.; Van Wart, H.; Poole, A. R. Enhanced Cleavage of Type II Collagen by Collagenases in Osteoarthritic Articular Cartilage. J. Clin. Invest. 1997, 7, 1534-1545.
4. (b) Pap, G.; Eberhardt, R.; Stürmer, I.; Machner, A.; Schwarzberg, H.; Roessner, A.; Neumann, W. Development of Osteoarthritis in the Knee Joints of Wistar Rats After Strenuous Running Exercise in a Running Wheel by Intracranial Self-Stimulation. Pathol. Res. Practice 1998,194, 41-47.
5. (c) Borden, P.; Solymar, D.; Sucharczuk, A.; Lindman, B.; Cannon, P.; Heller, R. A. Cytokine Control of Interstitial Collagenase and Collagenase-3 Gene Expression in Human Chondrocytes. J. Biol. Chem. 1996, 271, 23577-23581.
6. (a) Egeblad, M.; Werb, Z. New Functions for the Matrix Metalloproteases in Cancer Progression. Nat. Rev. 2002, 2, 161-174.
7. (b) Marshall, J. L.; Baidas, S.; Bhargava, P.; Rizvi, N. Matrix Metallproteinase Inhibitors in Cancer: An Update. IDrugs 2000, 3, 5, 518-524.
8. (c) Aoudjit, F.; Potworowski, E. F.; St-Pierre, Y. Bi-Directional Induction of Matrix Metallproteinase-9 and Tissue Inhibitor of Matrix Metallproteinase-1 During T Lymphoma/Endothetial Cell Contact: Implication of ICAM-1. J. Immunol. 1998, 160, 2967-2973.
9. (d) Gohji, K.; Nomi, M.; Hara, I.; Arakawa, S.; Kamidono, S. Influence of Cytokines and Growth factors on matrix metalloproteinase-2 production and invasion of human renal cancer. Urol. Res. 1998, 1, 33-37.
10. (e) Himelstein, B. P.; Canete-Soler, R.; Bernhard, E. J.; Dilks, D. W.; Muschel, R. J. Metalloproteinases in Tumor Progression: The Contribution of MMP-9. Invasion Metastasis 1994-95, 1-6, 246-258.
11. MacPherson, L. J.; Bayburt, E. K.; Capparelli, M. P.; Carroll, B. J.; Goldstein, R.; Justice, M. R.; Zhu, L.; Hu, S. I.; Melton, R. A.; Fryer, L.; Goldberg, R. L.; Doughty, J. R.; Spirito, S.; Blancuzzi, V.; Wilson, D.; O'Byrne, E. M.; Ganu, V.; Parker, D. T. Discovery of CGS 27023A, a Non-Peptidic, Potent, and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in Rabbits. J. Med. Chem. 1997, 40, 2525-2532.
12. (a) Broadhurst, M. J.; Brown, P. A.; Ballantyne, N.; Borkakoti, N.; Bottomley, K. M. K.; Cooper, M. I.; Eartherton, A. J.; Kilford, I. R.; Malsher, P. J.; Nixon, J. S.; Lewis, E. J.; Sutton, B. M.; Johnson, W. H. Design and Synthesis of the Cartilage Protective Agent (CPA, Ro32-3555). Bioorg. Med. Chem. Lett. 1997, 7, 17, 2299-2302.
13. (b) Lewis, E. J.; Bishop, J.; Bottomley, K. M. K, Bradshaw, D.; Brewster, M.; Broadhurst, M. J.; Brown, P. A.; Budd, J. M.; Elliott, L.; Greenham, A. K. ; Johnson, W. H.; Nixon, J. S.; Rose, F.; Sutton, B.; Wilson, K. Ro 32-3555, an orally active collagenase inhibitor, prevents cartillage breakdown in vitro and in vivo. Br. J. Pharmacol. 1997, 121, 540-546.
14. (c) Shaw, T.; Nixon, J. S.; Bottomley, K. M. Metalloproteinase inhibitors: new opportunities for the treatment of rheumatoid arthritis and osteoarthritis. Exp. Opin. Invest. Drugs 2000, 9, 7, 1469-1478.
15. Rasmussen, H. S.; McCann, P. P. Matrix Metalloproteinase Inhibition as a Novel Anticancer Strategy: A Review with Special Focus on Batimastat and Marimastat. Pharmacol. Ther. 1997, 75, 1, 69-75.
16. (a) Santos, O.; Mcdermott, C. D.; Daniels, R. G.; Appelt, K. Rodent pharmacokinetic and antitumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases. Clin. Exp. Metastasis 1997, 15, 499-508.
17. (b) Shalinsky, D. R.; Brekken, J.; Zou, H.; Kolis, S.; Wood, A.; Webber, S.; Appelt, K. Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations. Invest. New Drug 1999, 16, 303-313.
18. (a) Naglich, J. G.; Jure-Kunkel, M.; Gupta, E.; Fargnoli, J.; Henderson, A. J.; Lewin, A.; Talbott, R.; Baxter, A.; Bird, J.; Savopoulos, R.; Willis, R. ; Kramer, R. A.; Trail, P. A. Inhibition of Angiogenesis and Metastasis in Two Murine Models by the Matrix Metalloproteinase Inhibitor, BMS-275291. Cancer Res. 2001, 61, 8480-8485.
19. (b) Naglich, J. G.; Jure-Kunkel, M.; Gao, J.; Smith, D.; Talbott, R.; Henderson, A.; Kukral, D.; Lewin, A.; Jeyaseelan, R.; Cardenas, V.; Gupta, E.; Huang, M.; Bannister, R.; Trail, P. A. Activities of a synthetic matrix metalloproteinase inhibitor (MMPI), BMS-275291, in models of angiogenesis and tumor metastasis. Proc. Am. Assoc. Cancer Res. 2000, 41, 489: Abstr 3122.
20. Atley, L.; DeLustro, B.; Eugui, E.; Martin, R.; Eyre, D.; Caulfield, J. P. RS-130830, a selective inhibitor of collagenase-3 blocks the release of hydroxyproline and a metalloproteinase specific neoepitope, COLL II CTx, from bovine cartilage exposed to IL-1α. Arthritis Rheum. 1997, 40, (9, Suppl.): Abst 584.
21. Albert, D. H.; Morgan, D. W.; Magoc, T.; Tapang, P.; Kerzai, A.; Marcotte, P.; Elmore, I.; Glaser, K.; Pease, L.; Li, J.; Leal, J.; Michaelides, M.; Curtin, M.; Holms, J.; Wada, C.; Dai, Y.; Davidson, S. K. Preclinical pharmacology of ABT-518, a novel and potent inhibitor of gelatinase A and B with antitumor activity. Clin. Cancer Res. 2000, (6, Suppl.): Abstr 301.
22. Chollet, A. M.; Le Diguarher, T.; Kucharczyk, N.; Loynel, A.; Bertrand, M.; Tucker, G.; Guilbaud, N.; Burbridge, M.; Pastoureau, P.; Fradin, A.; Sabatini, M.; Fauchère, J. L.; Casara, P. Solid-phase Synthesis of α-substituted 3-Bisarylthio N-Hydroxy Propionamides as Specific MMP Inhibitors. Bioorg. Med. Chem. 2002, 10, 531-544.
23. Pikul, S.; McDow Dunham, K. L.; Almstead, N. G.; De, B.; Natchus, M.; Anastasio, M. V.; McPhail, S. J.; Snider, C. E.; Taiwo, Y. O.; Rydel, T.; Dunaway, C. M.; Gu, F.; Mieling, G. E. Discovery of Potent, Achiral Matrix Metalloproteinase Inhibitors. J. Med. Chem. 1998, 41, 3568-3571.
24. (a) Tamura, Y.; Watanabe, F.; Nakatani, T.; Yasui, K.; Fuji, M.; Komurasaki, T.; Tsuzuki, H.; Maekawa, R.; Yoshioka, T.; Kawada, K.; Sujita, K.; Ohtani, M. Highly Selective and Orally Active Inhibitors of Type IV Collagenase (MMP-9 and MMP-2): N-Sulfonylamino Acid Derivatives. J. Med. Chem. 1998, 41, 640-649.
25. (b) Tullis, J. S.; Laufersweiler, M. J.; VanRens, J. C.; Natchus, M. G.; Bookland, R. G.; Almstead, N. G.; Pikul, S.; De, B.; Hsieh, L. C.; Janusz, M. J.; Branch, T. M.; Peng, S. X.; Jin, Y. Y.; Hudlicky, T.; Oppong, K. The Development of New Carboxylic Acid-Based MMP Inhibitors Derived from a Cyclo-hexylglycine Scaffold. Bioorg. Med. Chem. Lett. 2001, 11, 1975-1979.
26. (c) Mattter, H.; Schudok, M.; Schwab, W.; Thorwart, W.; Barbier, D.; Billen, G.; Haase, B.; Neises, B.; Weithmann, K. U.; Wollmann, T. Tetrahydroisoquinoline-3-carboxylate Based Matrix-Metalloproteinase Inhibitors: Design, Synthesis and Structure-Activity Relationship. Bioorg. Med. Chem. 2002, 10, 3529-3544.
27. Fakstorp, J.; Raleigh, D.; Schniepp, L. E. Preparation and Reactions of Dialkoxytetrahydrofurans. J. Am. Chem. Soc. 1950, 72, 869-874.
28. (a) Graff, M.; Al Dilaimi, A.; Seguineau, P.; Rambaud, M.; Villiéras, J. La réaction de Wittig-Horner en milieu hétérogène IX. Bis aldolisation des phosphanates à partir des dialdéhydes aliphatiques en milieu aqueux peu basique. Synthèse de cyclenols fonctionnels. Tetrahedron Lett. 1986, 27, 14, 1577-1578.
29. (b) Villiéras, J.; Rambaud, M.; Graff, M. The Wittig-Horner reaction in heterogeneous media VIII. Cyclisation during the aldolisation step from aqueous glutaraldehyde. Synth. Commun. 1986, 16, 2, 149-156.
30. El-Bouz, M.; Wartski, L. 1,4-addition of lithiated derivatives from 1,3-dithianes to α-unsaturated aldehydes: a way to δ-carbonyl aldehydes. Tetrahedron Lett. 1980, 21, 2897-2900.
31. 4, from D-Arabinose. J. Org. Chem. 1988, 53, 832-836.
32. Dambrin, V.; Villiéras, M.; Moreau, C.; Amri, H.; Loupet, L.; Villiéras, J. Copper(I) mediated Highly Diastereoselective Conjugate Addition of Grignard Reagents to 2-Silyloxy cyclopentenecarboxylates. Tetrahedron Lett. 1996, 37, 35, 6323-6326.
33. Chollet, A. M.; Le Diguarher, T.; Murray, L.; Bertrand, M.; Tucker, G. C.; Sabatini, M.; Pierré, A.; Atassi, G.; Bonnet, J.; Casara, P. General Synthesis of α-Substituted 3-Bisaryloxy Propionic Acid Derivatives as Specific MMP Inhibitors. Bioorg. Med. Chem. Lett. 2001, 3, 11, 295-299.
34. Farina, V.; Krishnamurthy, V.; Scott, W. J. The Stille Reaction. Org. React. 1997, 50.
35. Mitsunobu, O. The Mistunobu Reaction. Synthesis 1981, 1-28.
36. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and therapeutic appplication of matrix metalloproteinase inhibitors. Chem. Rev. 1999, 99, 2735-2776 and references cited herein.
37. Massova, I.; Fridman, R.; Mobashery, S. Structural Insights into the Catalytic Domains o Human Matrix Metalloprotease-2 and Human Matrix Metalloprotease-9 Implications for Substrate Specificities. J. Mol. Model. 1997, 1, 3, 17-30 and references cited herein.
38. SYBYL 6.8, Tripos Inc., 1699 South Hanley Road, Saint-Louis, MO 63144, USA, running on an Octane R12000 Silicon Graphics workstation.
39. Halgren, T. A. MMFF VI. MMFF94s option for energy minimization studies. J. Comput. Chem. 1999, 20(7), 720.
40. Khokha, R. Suppression of the Tumorigenic and Metastatic Abilities of Murine B16-F10 Melanoma Cells In Vivo by the Overextression of the Tissue Inhibitor of the Metalloproteinases-1. J. Natl. Cancer Inst. 1994, 86, 4, 299-304.
41. Nagase, H.; Fields, C. G.; Fields, G. B. Design and Characterization of a Fluorogenic Substrate Selectively Hydrolyzed by Stromelysin 1 (Matrix Metalloproteinase-3). J. Biol. Chem. 1994, 269, 33, 20952-20957.
42. Bickett, D. M.; Green, M. G.; Berman, J.; Dezube, M.; Howe, A. S.; Brown, P. J.; Roth, J. T.; McGeehan, G. M. A high Through-put Fluorogenic Substrate for Interstitial Collagenase (MMP-1) and Gelatinase (MMP-9). Anal. Biochem. 1993, 212, 58-64.
43. Fidler, I. J. and Nicolson, G. L. Brief Communication: Organ Selectivity for Implantation Survival and Growth of B16 Melanoma Variant Tumor Lines. J. Natl. Cancer Inst. 1976, 57, 5, 1199-1202.